

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): September 12, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.

(Exact Name of Registrant as Specified in Its Charter)

California

(State or Other Jurisdiction of Incorporation)

333-198073

(Commission File Number)

02-0692322

(IRS Employer Identification No.)

**12744 San Fernando Road, Suite 400
Sylmar, California 91342**

(Address of Principal Executive Offices)

(818) 833-5000

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. REGULATION FD DISCLOSURE

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight ") intends to use during presentations made before groups and in hosting one-on-one meetings with individuals present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York City (the "Presentation Materials"), is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, Second Sight has posted the Presentation Materials on the Investor Relations section of Second Sight's website: <http://investors.secondsight.com>. The presentation will be webcast and available following the live presentation. The webcast can be viewed at: <http://wsw.com/webcast/rrshq27/eyes>. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No. Description

[99.1 Second Sight Medical Products, Inc. Investor Presentation dated September 2017](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 12, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ Thomas B. Miller

By: Thomas B. Miller
Chief Financial Officer



Enriching the lives of the blind
September 2017

Forward Looking Statements

NASDAQ: EYES



This presentation contains certain forward-looking information about Second Sight that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "strong," "up coming," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance.

In this document, we refer to information regarding potential markets for products and other industry data. We believe that all such information has been obtained from reliable sources that are customarily relied upon by companies in our industry. However, we have not independently verified any such information.

Forward-looking statements may address the following subjects among others: expected products, applications, customers, technologies and performance, coverage and insurance reimbursements, results of clinical studies, success of research and development and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties referred to in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report on Form 10-K as filed on March 16, 2017 and our other reports filed from time to time with the Securities and Exchange Commission. The audience is cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Second Sight Medical Products, Inc.

NASDAQ: EYES



We have created
an implantable
prosthesis that
enables useful
vision and a higher
quality of life



Restoring Vision With Neurostimulation

NASDAQ: EYES




Worlds First Bionic Eye

- Neurostimulation platform
- Addresses multiple forms of blindness
- Demonstrated clinical benefit
- **410+ issued patents**

Large Market Opportunity

- **8M blind from otherwise untreatable forms of blindness**
- Current indication: NLP/BLP Retinitis Pigmentosa
- Targets: AMD & all otherwise untreatable forms of blindness



Currently Available

- **Regulatory clearance in U.S., E.U. & other key markets**
- 250+ patients treated
- Clinical studies ongoing
- Planned for additional clinical indications

Reimbursed

- **Medicare coverage in 28 states**
- **Reimbursed in Germany, Italy, UK, and France (4 of the 5 largest European device markets)**
- U.S. reimbursement codes & outpatient rate established for 2017 (prelim 2018)

Video: Bionic Eye Gives Sight to the Blind

NASDAQ: EYES



<http://www.bloomberg.com/news/videos/2015-05-21/bionic-eyes-give-second-sight-to-the-blind>

Second Sight

Large Targeted Patient Population: 8+ Million

NASDAQ: EYES




- **End-Stage Retinitis Pigmentosa (<0.2M)**
 - Bare light or no light perception (completely blind)
 - Argus II® commercially available

- **Legally Blind RP Population**
 - Broader population with less vision loss
 - Next-gen Argus platform: software changes

- **Age-Related Macular Degeneration (AMD)**
 - Clinical trial in dry AMD underway in U.K.

- **Other Forms of Untreatable Blindness**
 - Eye trauma, optic nerve disease & other causes
 - Feasibility study begins in second half of 2017




Total Targeted Patient Population: ~8.2M

Second Sight



Functional vision restored by bypassing the damaged part of the retina to send visual signals to the healthy retinal cells



- 1 Using a camera housed in a patient's glasses, images are collected and converted into a series of small electrical pulses.
- 2 These pulses are transmitted wirelessly to an electrode array on the surface of the retina.
- 3 These pulses stimulate the remaining cells in the retina, resulting in the perception of patterns of light in the brain.

Patient Populations for ARGUS II



400,000 legally blind worldwide from Retinitis Pigmentosa (RP)

RP is an inherited genetic disorder that causes peripheral vision loss. People with RP typically lose all functional vision between the ages of 40 or 50.



2 million legally blind worldwide from Age-Related Macular Degeneration (AMD)


AMD causes loss of central vision and progresses to blindness. The patient population could potentially increase 2-3x its current size in the future.

Orion Technology – Our Next Generation

NASDAQ: EYES



Breakthrough Orion platform bypasses the damaged eye and/or optic nerve to send visual signals directly to the brain



- 1 The Orion is built on the Argus II platform leveraging decades of research
- 2 Camera housed in a patient's glasses collects images and converts into a series of small electrical pulses
- 3 These pulses are transmitted wirelessly to an electrode array on the surface of the brain, bypassing the eye and the optic nerve.
- 4 These pulses stimulate the visual cortex, resulting in the perception of patterns of light in the brain.

- The addressable market for Orion is an order of magnitude larger than for Argus II, with no other solutions available -

Patient Populations for Orion



Almost 6 million legally blind worldwide from other forms of untreatable blindness

Other diseases including glaucoma, diabetic retinopathy and eye trauma may render the eye or optic nerve nonfunctional and ultimately result in a complete loss of vision.

Second Sight

Chronic Visual Cortical Stimulation using “Off the Shelf” Device

NASDAQ: EYES




Second Sight sponsored a clinical trial at UCLA which was announced Q4 2016

- 30 year old with an 8 year history of bare light perception blindness

Methods:

Implantation of a Neurostimulator device with 2 parallel 4-contact leads implanted over the right medial occipital lobe.



Systematic manipulation of stimulation intensity, pulse width, frequency, and site of stimulation using laptop-based software.

Results:


All eight contacts produced phosphenes.

No serious adverse events.

Second Sight

Stimulation Thresholds Are Stable Over 7 Months

NASDAQ: EYES



Second Sight

FDA has approved initial Orion clinical trial

NASDAQ: EYES




Up to 5 bare light perception blind patients in 2 centers

- UCLA - University of California - LA
- Baylor College of Medicine, Houston

A third center is planned in Europe pending European Regulatory Approval.

Feasibility Study with multiple safety and utility endpoints.

The FDA has also requested that the Company conduct additional device testing and address outstanding questions. Second Sight has 45 days to respond to FDA's requests.



Second Sight

Established Technology Leadership

NASDAQ: EYES



CUMULATIVE TOTAL COMMERCIAL IMPLANTS BY QUARTER AND BY YEAR [EX. PRE-COMMERCIAL IMPLANTS]:



Second Sight

Neurostimulation Emerges as First Effective Treatment for Blindness

NASDAQ: EYES



Significant first mover advantage – Currently the only reimbursed treatment for blindness

Retinal Prosthesis Competitors	CE Mark	Widely Reimbursed in Europe	FDA Approved	Reimbursed in USA
Second Sight, Argus®II	✓	✓	✓	✓
Retina implant (Germany)	✓	✗	✗	✗
Pixium Vision (France)	✓	✗	✗	✗
Nidek Co., Ltd. (Japan)	✗	✗	✗	✗
Bionic Vision Technologies (Australia)	✗	✗	✗	✗
NanoRetina (Israel)	✗	✗	✗	✗
Other Therapies	CE Mark	Widely Reimbursed in Europe	FDA Approved	Reimbursed in USA
Stem Cells	✗	✗	✗	✗
Gene Therapy	✗	✗	✗	✗
Opto-Genetics	✗	✗	✗	✗
Transplant	✗	✗	✗	✗

Second Sight



Achievements-to-Date

What's Next?



- 7 of 12 MAC* jurisdictions (~62% of US population) with positive coverage decision
- Attained new CPT codes for initial programming and reprogramming of Argus II
- \$150k reimbursement rate set for 2017

- Continue coverage expansion to remaining MAC jurisdictions
- Maintain high success rate of prior authorization approvals for Medicare Advantage & commercial patients



- Coverage in England under "Commissioning through Evaluation" program
- Coverage in Germany under NUB (innovation funding) program
- Coverage in France under "Forfait Innovation" program
- Reimbursement in a key region of Italy

- Enroll 10 patient post-market study in UK under Commissioning through Evaluation (CtE) program
- Inclusion in standard payment system in France and Germany
- Pursuing reimbursement in Belgium and Turkey
- Pursuing reimbursement in additional regions of Italy


Goal: to offer Argus II to more patients/candidates worldwide

2017 Key Strategic Objectives

NASDAQ: EYES



Building a Foundation for Long-Term Growth




Strengthening Centers of Excellence

NASDAQ: EYES



Goal

Partner with leading medical institutions to establish a network of high-quality surgical centers that are capable of treating a higher volume of patients



Treating Better-Sighted Patients with Argus II Enhancements

NASDAQ: EYES



Clinical Testing of Current Argus II Technology in Better-Sighted RP Patients

Clinical Testing of Argus II Enhancements in Better-Sighted RP & AMD Patients

- New external components for streamlined appearance
- Software improvements for advanced image processing
- Improved retinal stimulation



Second Sight

Expanding into Potential 5.8M Patient Market with Orion

NASDAQ: EYES



- 30 year old female patient
- Neuropace RNS System (*approved to treat epilepsy*)
- Eight electrodes implanted
- Results showed each electrode generated a perceptible spot of light
- No serious adverse events

Select Financials

NASDAQ: EYES



(USD \$ in Thousands)	Q2 2017	Q2 2016	FY 2016	FY 2015
Implants	19	11	42	75
Revenue	\$2,236	\$1,037	\$3,985	\$8,950
Gross Profit (Loss)	1,109	(2,204)	(6,091)	3,657
Net Loss	(6,843)	(8,504)	(33,179)	(20,018)
Non-GAAP Adjusted Net Loss*	(6,586)	(6,197)	(24,812)	(17,007)

(USD \$ in Thousands)	Jun 30, 2017	Dec 31, 2016	Dec 31, 2015
Cash, cash equivalents & investments	\$18,129	\$10,875	\$15,960
Outstanding Debt	\$0	\$0	\$0

*Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory.

A Better Way of Life for Patients

NASDAQ: EYES



Improved
Orientation and
Mobility

Significant
Improvement in
Quality of Life



Greater
Independence

Enhanced
Connection to
Loved Ones

Second Sight

21

Second Sight Investment Highlights

NASDAQ: EYES



Technology Leadership

- First and only treatment approved for sale in the US, EU, Saudi Arabia, Turkey and Canada
- Robust IP portfolio with 500+ patents issued and pending; Over \$200M invested to date
- Significant first mover advantage with 5+ year lead over any other therapeutic option in U.S.

Large Market Opportunity

- RP, AMD and other untreatable forms of blindness totaling an estimated 8+ million people
- Significant unmet clinical need with proven clinical benefit

Increased Adoption of Argus II in 2017

- Centers of Excellence commercial model
- Technology enhancements to broaden RP target to better-sighted patients

Established Reimbursement in U.S. and Europe

- 2017 established rate of \$150K in U.S. with coverage in 28 states, or 62% of U.S. population (2018 preliminary rate of \$122K in U.S.)
- CPT codes to be established in July 2017 for post-surgery programming
- Reimbursed in 4 of 5 biggest European markets - Germany, Italy, France and UK

Robust R&D pipeline

- Argus II improvements to advance performance and expand markets
- The Orion platform represents a breakthrough for untreatable forms of blindness, and will be ready for clinical study in 2H 2017



Second Sight Medical Products, Inc.

12744 San Fernando Road

Suite 400

Sylmar, CA 91342

Main: 818-833-5000

www.secondsight.com

Robert Greenberg MD, PhD
Chairman

Direct: 818-833-5050

bob@secondsight.com

Retail Investor Relations

Greg Falesnik

Managing Director

MZ North America

Direct: 949-385-6449

Greg.Falesnik@mzgroup.us

Institutional Investor Relations

Lisa Wilson

President

In-Site Communications, Inc.

Direct: 212-452-2793

lwilson@insitecony.com